相关实验视频
Updated: Jun 9, 2025

07:50
Establishment of a Clinic-based Biorepository
Published on: May 29, 2017
6.5K
探索皮肤状细胞癌的潜在生物标志物和分子机制,基于生物信息学
Jiayue Qi1,2, Qingqing Guo1,2, Jia Bai1
1Department of Dermatology, First Medical Center, Chinese PLA General Hospital, Beijing, People's Republic of China.
OncoTargets and therapy
|October 31, 2024
概括
鉴定了皮肤状细胞癌 (cSCC) 的生物标志物CCNA2,CCNB2和UBE2C. 涉及NEAT1,H19和miR-148a-3p/miR-140-3p的竞争性内源性RNA网络可能会推动cSCC的进展,提供新的治疗途径.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 皮肤状细胞癌 (cSCC) 是一种常见的恶性瘤,具有转移的高潜力.
- 识别可靠的生物标志物和理解分子途径对于有效的cSCC管理至关重要.
研究的目的:
- 为了确定皮肤状细胞癌 (cSCC) 的新生物标志物.
- 阐明cSCC进展背后的分子机制.
- 探索cSCC的潜在诊断和治疗点.
主要方法:
- 公开数据集的基因表达差异分析 (GSE66359,GSE117247).
- 蛋白与蛋白相互作用 (PPI) 和加权基因共表达网络分析 (WGCNA) 用于枢纽基因识别.
- 接收器操作特征 (ROC) 曲线分析用于诊断性能评估和免疫组织化学用于验证.
- 使用生物信息学工具构建竞争的内源RNA (ceRNA) 网络.
主要成果:
- 确定了505个上调和522个下调的差异表达基因 (DEG).
- 发现了四个具有高诊断精度 (AUC>0.9) 的枢纽基因,包括CCNA2,CCNB2和UBE2C,这些基因在cSCC组织中显著过度表达.
- 构建了三个ceRNA网络,突出了NEAT1,H19,miR-148a-3p,miR-140-3p,CCNA2和UBE2C的潜在调节作用.
结论:
- CCNA2,CCNB2和UBE2C被确定为cSCC的新型诊断生物标志物.
- NEAT1/H19-hsa-miR-148a-3p-CCNA2和NEAT1-hsa-miR-140-3p-UBE2C ceRNA网络可能在cSCC的发病过程中发挥作用.
- 这些发现为cSCC诊断和治疗提供了潜在的新途径.
相关概念视频
Skin Cancer
3.8K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
3.8K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

